Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients
Article first published online: 20 MAY 2013
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 75, Issue 6, pages 1497–1505, June 2013
How to Cite
Voon, P. J., Yap, H. L., Ma, C.-Y.-T., Lu, F., Wong, A. L. A., Sapari, N. S., Soong, R., Soh, T. I. P., Goh, B.-C., Lee, H.-S. and Lee, S.-C. (2013), Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. British Journal of Clinical Pharmacology, 75: 1497–1505. doi: 10.1111/bcp.12021
- Issue published online: 20 MAY 2013
- Article first published online: 20 MAY 2013
- Accepted manuscript online: 1 NOV 2012 06:40AM EST
- Manuscript Accepted: 26 OCT 2012
- Manuscript Received: 22 JUL 2012
- National Medical Research Council, Singapore. Grant Numbers: NMRC/CSI/0009/2006, NMRC/CSI/0015/2009, NMRC/CG/NCIS/2010
- Cancer Science Institute Singapore. Grant Number: R-713-001-011–271
- ClinicalTrials.gov. Grant Numbers: NCT00212082, NCT00669773
Options for accessing this content:
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.